Bionaut Labs

Bionaut Labs is a biotechnology start-up focused on treating central nervous system disorders (CNS) with its Bionaut precision medicine treatment modality. Bionaut uses remote-controlled microscale robots to deliver biologics, nucleic acids, or small molecule therapies locally to targeted CNS disease areas. Through precision localized brain targeting, Bionaut therapeutics could offer better efficacy and safety that cannot be achieved by other traditional treatment modalities. Two of the company's earliest indications are for gliomas and Huntington's disease. The Bionaut therapeutic-containing drug targets a disease similarly to how a traditional modality targets a disease. Bionauts are custom-engineered therapeutic micro-robots that target payloads to specific locations in the body. Bionauts can be constructed in different versions with custom geometries and surface characteristics. Smaller than a millimeter, they contain moving parts controlled remotely by a compact magnetic controller, allowing them to move.

Bionaut Labs has raised $69.2M in total funding across 3 rounds. The company is currently at the B stage. Key investors include OurCrowd, Upfront Ventures, Mayo Clinic Platform.

Bionaut Labs was founded in 2016 by Aviad Maizels (Co-founder & Executive Chairman), Michael Shpigelmacher (Co-founder & CEO), Alexander Shpunt (Co-founder ).

Bionaut Labs operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drug Delivery, with core technologies in Machinery & Robotics. Target customers: Healthcare & Life Sciences, Healthcare, Providers.

Bionaut Labs is based in Arieh Shenkar Street 1, Herzliya, Israel, Center District. The company also has offices abroad.